Canaccord Genuity Keeps Boston Scientific at Buy, Cuts Target to $48
Canaccord Genuity maintained its Buy rating on Boston Scientific and lowered its price target to $48 from $66.
Related stories
Church & Dwight Reports Q3 Results, Raises 2026 Sales Outlook
Q3 net sales rose 1.0% to $1.602B and adjusted EPS rose 13.6% to $0.92, both above outlook. The company now sees 2026 reported sales up about 0.5% and adjusted EPS growth of about
M impact | EQUITY | Oct 30, 2026, 10:55 AM UTC
Salesforce to Acquire Defense Tech Firm Rune Technologies
Salesforce said it signed a definitive agreement to acquire Rune Technologies, expanding its military AI logistics capabilities.
M impact | EQUITY | Oct 30, 2026, 10:51 AM UTC
Alliant Energy Reports Higher Q3 Non-GAAP Earnings and Revenue
Alliant Energy reported increases in Q3 non-GAAP earnings and revenue.
M impact | EQUITY | Oct 30, 2026, 10:47 AM UTC
Kenvue Reports Third-Quarter Earnings
M impact | EQUITY | Oct 30, 2026, 10:45 AM UTC
Intel Shares Fall 25.4% After Weak Q4 Guidance
Intel forecast fourth-quarter adjusted EPS of 25 cents versus the 43-cent analyst estimate, and revenue of $15 billion to $16 billion versus $17.05 billion expected. Shares fell 25
H impact | EQUITY | Oct 30, 2026, 10:39 AM UTC
Intel Shares Fall About 25% Premarket After Results
Intel shares were down roughly 25% before the bell after the company posted results after hours yesterday. The move could erase around $120 billion from its market value.
H impact | EQUITY | Oct 30, 2026, 10:38 AM UTC